1.Abnormal calcium handling properties underlie
familial hypertrophic cardiomyopathy pathology in patient-specific
induced pluripotent stem cells.
Lan F, Lee AS, Liang P,
Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez
OJ,Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis
R, Yamaguchi Y, Ashley EA, Bers
DM, Robbins RC, Longaker MT, Wu JC.
Cell Stem Cell. 12(1):101-13 (2013)
2.Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.
Sun
N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG,
Hu S, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP,
Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC.
Sci Transl Med. 4:130 (2012)
3.A
novel method of selecting human embryonic stem cell-derived
cardiomyocyte clusters for assessment of potential to influence QT
interval.
Yamazaki K, Hihara T, Taniguchi T, Kohmura N, Yoshinaga T, Ito M, Sawada K.
J Toxicol In Vitro. 26(2):335-342 (2011)
4.Usefulness
of field potential as a marker of embryonic stem cell-derived
cardiomyocytes, and endpoint analysis of embryonic stem cell test.
Koseki N, Deguchi J, Yamada T, Funabashi H, Seki T.
Toxicol Sci. 35(6):899-909 (2010)
5.Improvement of the embryonic stem cell test endpoint analysis by use of field potential detection.
Koseki N, Deguchi J, Yamada T, Funabashi H, Seki T.J Toxicol Sci. 35(5):619-29 (2010)
6.Progressive
maturation in contracting cardiomyocytes derived from human embryonic
stem cells: Qualitative effects on electrophysiological responses to
drugs.
Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N.Stem Cell Res. 4(3):201-13 (2010) |
